Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by WarrantOfficeron Dec 20, 2023 9:04am
169 Views
Post# 35793464

New Strategic Partnership

New Strategic PartnershipThis strategic partnership is a testament to Voyageur's unwavering commitment to excellence and innovation. It grants the distributor exclusive rights within their designated territory, acknowledging their key role in securing regulatory licensing for Voyageur's suite of five barium contrast products. Given the sensitivity and competitive nature of the barium contrast market, Voyageur remains steadfast in maintaining strict confidentiality regarding client information, pricing, and sales volumes.

I have had several days to study the latest PR. There is no avenue to follow up on the new Strategic Partnership in Central America. Is this of a concern to anyone? A person can research historic PR's and read the vagueness of statements that did not develop into forward traction. I am playing the devil's advocate hand, but is anyone else going hmmm?

<< Previous
Bullboard Posts
Next >>